Sequoia Financial Advisors LLC Buys 21,240 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Sequoia Financial Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 12.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 190,940 shares of the company’s stock after buying an additional 21,240 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $6,469,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in TEVA. Aster Capital Management DIFC Ltd acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $25,000. Cornerstone Planning Group LLC raised its holdings in shares of Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after acquiring an additional 755 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares in the last quarter. Finally, Global Retirement Partners LLC lifted its position in shares of Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after purchasing an additional 292 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on TEVA shares. Barclays boosted their price objective on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Leerink Partners initiated coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday. They issued an “outperform” rating and a $45.00 price objective for the company. UBS Group raised their target price on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, September 4th. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. Finally, Weiss Ratings lowered Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday. Ten investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average price target of $43.10.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $37.01 on Friday. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. The stock’s 50 day moving average price is $34.91 and its 200-day moving average price is $33.37. The stock has a market capitalization of $43.13 billion, a PE ratio of 61.68, a price-to-earnings-growth ratio of 4.53 and a beta of 0.87. Teva Pharmaceutical Industries Ltd. has a 52-week low of $18.21 and a 52-week high of $38.37.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The business had revenue of $4.14 billion during the quarter. On average, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.94 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.